Business
Travere Therapeutics Announces Presentations and Posters at American Society of Nephrology Kidney Week 2022
Data support the Company’s lead investigational product candidate sparsentan SAN DIEGO, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:
About this update from Travere Therapeutics, Inc.
[{"type":"text","content":"Data support the Company’s lead investigational product candidate sparsentan\nSAN DIEGO, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present data from its sparsentan programs, including long-term clinical data from the ongoing Phase 2 DUET Study in focal segmental glomerulosclerosis (FSGS), as well as non-clinical data exploring the potential for sparsentan to protect kidney function at the American Society of Nephrology (ASN) Kidney Week 2022. The company will also present data on the role of proteinuria in IgA nephropathy (IgAN) and on the humanistic burden of IgAN on patients and caregivers. ASN Kidney Week 2022 is being held November 3-6, 2022, in Orlando, Florida. Oral Presentations Sparsentan Improves Glomerular Endothelial and Podocyte Functions and Augments Protective Tissue Repair in a Mouse Model of Focal Segmental Glomerulosclerosis (FSGS) Session: Glomerular Diseases: From Bench to BedsideOral Presentation: FR-OR56Location: Session Room: W414 (Orange County Convention Center, West Building)Date & Time: November 4, 2022, from 5:15 to 5:24 p.m. ET Long-Term Efficacy and Safety of Sparsentan in FSGS: 240-Week Analysis of the DUET Open-Label Extension (OLE)Session: Glomerular Diseases: From Bench to BedsideOral Presentation: FR-OR57 Location: W414 (Orange County Convention Center, West Building) Date & Time: November 4, from 5:24 to 5:33 p.m. ET Poster Presentations Evaluating the Predictors of Structural Features in Kidney Biopsies from Adults with Focal Segmental Glomerulosclerosis Poster #: TH-PO478Session: Glomerular Diseases: Clinical, Outcomes, Trials – IDate, Time & Location: November 3, 2022, from 10 a.m. to 12 p.m. ET, Hall E Proteinuria and Its Association With Disease Progression in IgA Nephropathy: Analysis of the UK National RaDaR IgA Nephropathy Cohort Poster #: TH-PO494 Session: Glomerular Diseases: Clinical, Outcomes, Trials - I Date, Time & Location: November 3, 2022, from 10 a.m. to 12 p.m. ET, Hall E Health State Utility Values for Immunoglobulin A Nephropathy (IgAN) Poster #: TH-PO496Session: Glomerular Diseases: Clinical, Outcomes, Trials – IDate, Time & Location: November 3, 2022, from 10 a.m. to 12 p.m. ET, Hall E Effect of Multiple Doses of Sparsentan on the Single-Dose Pharmacokinetics of Dapagliflozin: Op...